Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

Inclusion Criteria: * Male or female, aged 18 to 65 years * Subjects with SAR for at least 2 years * At least one serum-specific IgE test for an allergen associated with the onset of allergic rhinitis during the current season or the same period * Subjects who did not achieve satisfactory efficacy from Standard-of-Care prior to screening * Subjects who experienced nasal symptoms for ≥ 2 days, or nasal and ocular symptoms for ≥ 1 day; with rTNSS ≥ 1 prior to randomization Exclusion Criteria: * Combined with non-allergic rhinitis, such as drug-induced rhinitis, vasomotor rhinitis, non-allergic rhinitis with eosinophilia syndrome, a history of acute or chronic sinusitis * Subjects with perennial allergic rhinitis (PAR) * Underwent any nasal or sinus surgery within 1 year prior to screening * Presence of glaucoma, cataract, ocular herpes simplex, infectious conjunctivitis, or other ocular infections * Clinically significant conditions upon the judgement of investigator * Subjects with concomitant asthma who, upon the judgement of investigator, require inhaled corticosteroid treatment during the study * The laboratory results at screening: a) white blood cell (WBC) \< 2.5×10\^9/L; b) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.0 ×upper limit of normal (ULN) or total bilirubin \> 1.5 ×ULN; c) Serum creatinine (Cr) \> 1.5 × ULN * Received treatment with similar drugs (e.g., Omalizumab) or used LP-003 Injection within 6 months prior to screening * Recei…